• GT Biopharma will hold its annual shareholder meeting in Los Angeles on Aug. 14, 2026.
• Shareholders will vote to elect four directors and to ratify Weinberg & Company as independent auditor for the year ending Dec. 31, 2026.
• An advisory vote on executive compensation is also on the agenda.
• Investors will consider a reverse stock split in a 1-for-10 to 1-for-30 range, paired with a cut in authorized shares to 25,000,000 common and 1,500,000 preferred.
• Other items include adding 3,500,000 shares to the 2022 incentive plan pool and adopting a 2% annual evergreen increase through fiscal 2036.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029362), on June 18, 2026, and is solely responsible for the information contained therein.